Výsledky vyhledávání - "Stella Redpath"

Data from Non–Small Cell Lung Cancers with Kinase Domain Mutations in the Epidermal Growth Factor Receptor Are Sensitive to Ionizing Radiation

Autor: Chaitanya S. Nirodi, John D. Minna, Jerry W. Shay, Adi F. Gazdar, Luc Girard, Stella Redpath, Robert Graves, Michael Peyton, Michael D. Story, Mitsuo Sato, Amit K. Das

Non–small cell lung cancers (NSCLCs) bearing mutations in the tyrosine kinase domain (TKD) of the epidermal growth factor receptor (EGFR) often exhibit dramatic sensitivity to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Ionizing ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a554f9cb73df66f3467158937fd9ace4
https://doi.org/10.1158/0008-5472.c.6494373.v1

Zobrazit plný text záznamu

Understanding Factors Associated With Anaplastic Lymphoma Kinase Testing Delays in Patients With Non–Small Cell Lung Cancer in a Large Real-World Oncology Database

Autor: Yan Xiao, Denise Croix, Timothy Craig Allen, Julia Engstrom-Melnyk, Eric H. Bernicker, Stella Redpath, Baiyu Yang, Anup Abraham, R. Shah

Publikováno v: Archives of Pathology & Laboratory Medicine. 146:975-983

Context.— With multiple therapeutic options available for patients with advanced non–small cell lung cancer, the timely ordering and return of results to determine therapy are of critical importance. Objective.— To assess factors impacting anap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2d9d0bb39a7ba2631e75af66e7a1630
https://doi.org/10.5858/arpa.2021-0029-oa

Zobrazit plný text záznamu

Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data

Autor: Eric H. Bernicker, Julia Engstrom-Melynk, Baiyu Yang, Yan Xiao, Denise Croix, Stella Redpath, Jaya Madala, R. Shah, Timothy Craig Allen, Anup Abraham

Publikováno v: Oncotarget

Objective: This study assessed the prevalence of anaplastic lymphoma kinase (ALK) rearrangements in US oncology practices. Materials and Methods: Using a nationwide real-world database, we included adults with advanced non-small cell lung cancer (aNS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec3bd7a320a7033f040a098b51200c5d
http://europepmc.org/articles/PMC8590819

Zobrazit plný text záznamu

Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers

Autor: Denise Croix, Timothy Craig Allen, Yan Xiao, R. Shah, Stella Redpath, Eric H. Bernicker, Julia Engstrom-Melnyk, Anup Abraham, Jaya Madala, Baiyu Yang

Publikováno v: The Oncologist

Background National Comprehensive Cancer Network (NCCN) guidelines recommend biomarker testing as the first step in the management of patients with advanced non‐small cell lung cancer (aNSCLC). We assessed anaplastic lymphoma kinase (ALK) testing r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6f4b71bd06d8cadd302351da2746732
https://doi.org/10.1002/onco.13779

Zobrazit plný text záznamu

Prevalence of ALK mutations in advanced NSCLC patients in the United States: Analysis with a real world oncology database

Autor: Eric H. Bernicker, Jaya Madala, Denise Croix, Yan Xiao, R. Shah, Julia Engstrom-Melnyk, Stella Redpath, Timothy Craig Allen, Anup Abraham, Baiyu Yang

Publikováno v: Journal of Clinical Oncology. 38:e21586-e21586

e21586 Background: ALK mutation rate is widely reported to be 3-7% of advanced non-small cell lung carcinoma (aNSCLC) patients. A cross-sectional study to assess the prevalence of ALK mutations in the real world was performed on the nationwide Flatir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b218bc73b7e172a69290f681588447a
https://doi.org/10.1200/jco.2020.38.15_suppl.e21586

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání